High Δnp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia

Blood

Volumn 126, Issue 20, 2015, Pages 2302-2306

  Lucena Araujo, Antonio R ^a   Kim, Haesook T ^b   Thomé, Carolina ^a   Jacomo, Rafael H ^a   Melo, Raul A ^c   Bittencourt, Rosane ^d   Pasquini, Ricardo ^e   Pagnano, Katia ^f   Glória, Ana Beatriz F ^g   De Lourdes Chauffaille, Maria ^h   Athayde, Melina ^g   Chiattone, Carlos S ⁱ   Mito, Ingrid ^d   Bendlin, Rodrigo ^e   Souza, Carmino ^f   Bortolheiro, Cristina ⁱ   Coelho Silva, Juan L ^j   Schrier, Stanley L ^k   Tallman, Martin S ^l   Grimwade, David ^m   Ganser, Arnold ⁿ   Berliner, Nancy ^o   Ribeiro, Raul C ^p   Lo Coco, Francesco ^q,r   Löwenberg, Bob ^s   Sanz, Miguel A ^t   Rego, Eduardo M ^a   more..

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^h FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^j FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

^m KING'S COLLEGE LONDON   (United Kingdom)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o HARVARD MEDICAL SCHOOL   (United States)

^p ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^q UNIVERSITY OF ROME TOR VERGATA   (Italy)

^r IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^s ERASMUS MEDICAL CENTER   (Netherlands)

^t UNIVERSITY OF VALENCIA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; NP73 PROTEIN; RETINOIC ACID; RNA; TAP73 PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ISOPROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HAZARD RATIO; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ALTERNATIVE RNA SPLICING; BIOLOGICAL MODEL; BIOSYNTHESIS; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ALTERNATIVE SPLICING; CHILD; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PROPORTIONAL HAZARDS MODELS; PROTEIN ISOFORMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84948948591     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-623330     Document Type: Article

References (28)

1. Grob TJ, Novak U, Maisse C, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001; 8(12):1213-1223.
2. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997;389(6647): 191-194.
3. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 2002;62(3):636-641.
4. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science. 2000; 289(5477):304-306.
5. Buhlmann S, Pützer BM. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim Biophys Acta. 2008; 1785(2):207-216.
6. Meier M, den Boer ML, Meijerink JP, et al. Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia. 2006;20(8): 1377-1384.
7. Lucena-Araujo AR, Panepucci RA, dos Santos GA, et al. The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity. Br J Haematol. 2008;142(1):74-78.
8. Rego EM, Kim HT, Ruiz-Argüelles GJ, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013;121(11): 1935-1943.
9. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005; 61(1):92-105.
10. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543-2546.
11. Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4): 1247-1253.
12. Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol. 2014; 93(12):2001-2010.
13. Montesinos P, Rayón C, Vellenga E, et al; PETHEMA; HOVON Groups. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2011;117(6):1799-1805.
14. Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. Br J Haematol. 2014;166(4): 540-549.
15. Sunter NJ, Scott K, Hills R, et al. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood. 2012;119(1): 196-205.
16. Domínguez G, García JM, Penã C, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol. 2006;24(5):805-815.
17. Leung TH, Wong SC, Chan KK, Chan DW, Cheung AN, Ngan HY. The interaction between C35 and DNp73 promotes chemo-resistance in ovarian cancer cells. Br J Cancer. 2013;109(4): 965-975.
18. Soldevilla B, Díaz R, Silva J, et al. Prognostic impact of DTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res. 2011;17(18):6029-6039.
19. Nakagawa T, Takahashi M, Ozaki T, et al. Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells. Cancer Lett. 2003;197(1-2):105-109.
20. Slade N, Zaika AI, Erster S, Moll UM. DeltaNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ. 2004;11(3):357-360.
21. Sayan BS, Yang AL, Conforti F, et al. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci USA. 2010; 107(29):12877-12882.
22. Dulloo I, Gopalan G, Melino G, Sabapathy K. The antiapoptotic DeltaNp73 is degraded in a c-Jundependent manner upon genotoxic stress through the antizyme-mediated pathway. Proc Natl Acad Sci USA. 2010;107(11):4902-4907.
23. Kartasheva NN, Contente A, Lenz-Stöppler C, Roth J, Dobbelstein M. p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene. 2002;21(31):4715-4727.
24. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V. DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur. Cell Death Differ. 2004;11(6):685-687.
25. Longo L, Trecca D, Biondi A, et al. Frequency of RAS and p53 mutations in acute promyelocytic leukemias. Leuk Lymphoma. 1993;11(5-6):405-410.
26. Soldevilla B, Millán CS, Bonilla F, Domínguez G. The TP73 complex network: ready for clinical translation in cancer? Genes Chromosomes Cancer. 2013;52(11):989-1006.
27. Concin N, Hofstetter G, Berger A, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res. 2005;11(23): 8372-8383.
28. Lo-Coco F, Avvisati G, Vignetti M, et al; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-121.